MARTINSRIED/MUNICH, Germany, Sept. 1 /PRNewswire-FirstCall/ -- U.S.
Research and Development Facilities in Waltham/Boston, Mass. and Princeton,
N.J. -- GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; Nasdaq:
GPCB) today announced that the Company will present at BioCentury's 12th
NewsMakers in the Biotech Industry Investment Conference in New York, New
York.
The presentation will be given by Mirko Scherer, Ph.D., Chief Financial
Officer of GPC Biotech, and is scheduled for Friday, September 9, 2005, 8:30
AM EDT/14:30 CET at the Sheraton New York Hotel & Towers. The presentation
will be webcast live and will be accessible through the GPC Biotech Web site
at http://www.gpc-biotech.com. A replay will be available via the Web site
following the live event.
GPC Biotech AG is a biopharmaceutical company discovering and developing
new anticancer drugs. The Company's lead product candidate -- satraplatin --
is currently in a Phase 3 registrational trial as a second-line chemotherapy
treatment in hormone-refractory prostate cancer following successful
completion of a Special Protocol Assessment by the U.S. FDA and receipt of a
Scientific Advice letter from the European central regulatory authority, EMEA.
The FDA has also granted fast track designation to satraplatin for this
indication. Other anticancer programs include: a monoclonal antibody with a
novel mechanism-of-action against a variety of lymphoid tumors, currently in
Phase 1 clinical development, and a small molecule broad-spectrum cell cycle
inhibitors program, currently in pre-clinical development. The Company also
has a number of drug discovery programs that leverage its expertise in kinase
inhibitors. GPC Biotech has a multi-year alliance with ALTANA Pharma AG
working with the ALTANA Research Institute in the U.S., which provides GPC
Biotech with revenues through mid-2007. GPC Biotech AG is headquartered in
Martinsried/Munich (Germany). The Company's wholly owned U.S. subsidiary has
research and development sites in Waltham, Massachusetts and Princeton, New
Jersey. For additional information, please visit the Company's Web site at
http://www.gpc-biotech.com.
For further information, please contact:
GPC Biotech AG
Martin Braendle
Associate Director, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565-2693
ir@gpc-biotech.com
In the U.S.:
Laurie Doyle
Associate Director, Investor Relations & Corporate Communications
Phone: +1 781-890-9007 X267
usinvestors@gpc-biotech.com
SOURCE GPC Biotech AG
 back to top
Related links:
http://www.gpc-biotech.com
CONTACT:
Martin Braendle, Associate Director, Investor
Relations & Corporate Communications, +49 (0)89 8565-2693,
ir@gpc-biotech.com, or In the U.S.: Laurie Doyle, Associate
Director, Investor Relations & Corporate Communications,
+1-781-890-9007 ext. 267, usinvestors@gpc-biotech.com, both of
GPC Biotech AG
|
